ArticleThe oncologist2012
Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
Article in The oncologist, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Evaluation of Systemic Treatments of Small Intestinal Adenocarcinomas: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Clinical practice guidelines for duodenal cancer 2021.Journal of gastroenterology · 2022Guideline
- A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.International journal of clinical oncology · 2017Trial
- Clinical practice guidelines for duodenal cancer 2025.Journal of gastroenterology · 2026Review
- Long-term survival outcomes of duodenal adenocarcinoma: A cohort study with 15-year single-center experience.World journal of gastrointestinal surgery · 2025Article
- Effectiveness of Palliative Chemotherapy and Associated Prognostic Factors in Advanced Small Bowel Adenocarcinoma: A Propensity Score-Matched Analysis.Cancer management and research · 2025Article
- Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study.JCO global oncology · 2024Observational
- Efficacy of lymph node dissection for duodenal cancer according to the lymph node station.Annals of gastroenterological surgery · 2024Article
- Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia.Molecular and clinical oncology · 2023Article
- Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2023Review
- Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives.Cancers · 2022Review
- Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management.Current oncology (Toronto, Ont.) · 2022Review
- Article
- Efficacy of surgery and chemotherapy for stage IV small bowel adenocarcinoma: A population-based analysis using Surveillance, Epidemiology, and End Result Program database.Cancer medicine · 2020Article
- A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.Cancer medicine · 2020Article
- Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?Clinical Medicine Insights. Oncology · 2020Article
- Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.Targeted oncology · 2019Article
- Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice.United European gastroenterology journal · 2019Article
- A pathological complete response by chemotherapy with S-1 and oxaliplatin for a locally advanced duodenal adenocarcinoma in Lynch syndrome: a case report.Surgical case reports · 2019Article
- Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2019Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo standard chemotherapy regimen has been established for unresectable or recurrent small bowel adenocarcinoma (SBA).
methodsClinical courses of 132 patients with unresectable or recurrent SBA who received chemotherapy at 41 institutions in Japan were reviewed retrospectively. Patients were classified into five groups according to first-line chemotherapy regimens: fluoropyrimidine monotherapy (group A), fluoropyrimidine-cisplatin (group B), fluoropyrimidine-oxaliplatin (group C), fluoropyrimidine-irinotecan (group D), and other regimens (group E).
resultsThe number of patients in each group was as follows: groups A, 60 patients; group B, 17 patients; group C, 22 patients; group D, 11 patients; and group E, 22 patients. Median progression-free survival (PFS) times were as follows: group A, 5.4 months; group B, 3.8 months; group C, 8.2 months; group D, 5.6 months; and group E, 3.4 months. Median overall survival (OS) times were as follows: group A, 13.9 months; group B, 12.6 months; group C, 22.2 months; group D, 9.4 months; and group D, 8.1 months. Patients in group C achieved significantly longer PFS times and substantially (but not significantly) longer OS times than patients in group A. After adjusting for clinical background characteristics, fluoropyrimidine-oxaliplatin therapy was a significant positive prognostic factor for PFS and OS times.
conclusionThe results suggest that fluoropyrimidine-oxaliplatin combination therapy is the most promising first-line chemotherapy regimen for unresectable or recurrent SBA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.